The estimated Net Worth of Richard M. Traynor is at least $8.06 Milione dollars as of 1 April 2024. Mr Traynor owns over 13,295 units of Certara stock worth over $1,963,224 and over the last 4 years he sold CERT stock worth over $6,096,600.
Mr has made over 23 trades of the Certara stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 13,295 units of CERT stock worth $145,979 on 1 April 2024.
The largest trade he's ever made was selling 73,000 units of Certara stock on 15 November 2021 worth over $2,772,540. On average, Mr trades about 8,354 units every 46 days since 2020. As of 1 April 2024 he still owns at least 178,800 units of Certara stock.
You can see the complete history of Mr Traynor stock trades at the bottom of the page.
Richard M. Traynor is the Sr. VP & Gen. Counsel at Certara.
Mr Traynor is 49, he's been the Sr. VP & Gen. Counsel of Certara since . There are 3 older and 2 younger executives at Certara. The oldest executive at Certara, Inc. is Leif E. Pedersen, 57, who is the Pres of Software.
Richard's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman e Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: